On October 14-15, 2021, hosted by Sino-American Pharmaceutical Professionals Association – China (SAPA-China), and guided and organized by the Management Committee of Suzhou High-tech Zone and the Management Committee of Suzhou Hushuguan Economy and Technology Development Zone, the Opportunity and Challenge for Chinese Biological Medicine Development and SAPA2021 China kicked off in Shishan International Convention Center in Suzhou High-tech Zone. 

A total of over 1,800 famous domestic and foreign scholars and entrepreneurs attended the event online or actually onsite, including Gao Fu, Academician of the Chinese Academy of Sciences, Director of China CDC; Joachim Frank, 2017 Nobel Laureate in Chemistry, Professor of Biological Science, University of Columbia; Rober Langer, Fellow of American Academy of Science, and National Academy of Engineering, Winner of American Science and Technology Invention Award, President of the FDA Scientific Advisory, and Professor of the Massachusetts Institute of Technology; Shi Yufang, Fellow with Academia Europaea; Hu Jiangbin, Dean of SAPA-China. Extensive exchanges were conducted on topics such as the ecosystem of Chinese pharmaceutics and biological technology development, strategies to promote drug innovation and frontier technologies. The event involved many sectors, including innovative drug target research and development; pre-clinical and clinical medicinal research; process development and production of small molecular chemicals and macromolecular biological drugs; market access registration and application of products; product commercialization and marketing; research and development and production technology of generic drugs. The event featured over 120 exhibitors and 8,000 audiences.

Noahpharm was also present. Because of the booth with brand characteristics and rich exhibition content, it not only attracted many old and new friends, but also caught plenty of media attention. Noahpharm was bustling. Many old and new friends came, negotiating business cooperation, exchanging industry prospect or deepening friendship.

With the national strategy of “innovation-driven development”, Chinese pharmaceuticals is ready to move forward through innovation. Many exceptional pharmaceuticals are becoming the pioneers, practitioners and leaders of domestic medical innovation. Led by the publicly traded company Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (stock code: 688621), Noahpharm will adhere to the service tenet of "win-win, trust, innovation and efficiency", speed up product research and development and marketing, and assist prosperous research and development of biological product. Noahpharm is ready to reshape research and development value system, drive innovation and achieve long-term development value.

Since its founding, Noahpharm has been emphasizing virtue and honoring commitment. With the tenet of professionalism, reliability and innovation, Noahpharm keeps exploring in-depth partnership and co-growth with domestic and foreign pharmaceutical and medical device manufacturers. With support by many customers and upgrade of protocol design and service, Noahpharm has emerged as one of noted suppliers in the domestic CRO sector. 

In the future, Noahpharm will keep striving for excellence, and attempt to reward customers with optimal protocol design and precise project operation. While honoring the service commitment of “customer centric and scientific innovation”, the company is ready to join hands with vast customers and ascend new heights!